Physician

Nathan Terry Rich, M.D.

According to 2025 Medicare claims, Nathan Rich, M.D. (NPI: 1396778148) practices medical oncology in the Provo-Orem-Lehi, UT market, with the plurality of this provider's patient population coming from Utah, UT. This provider's primary affiliated billing organization is UTAH CANCER SPECIALISTS PC (NPI: 1619925369; TIN: 870519691) and primary practice location at 84604-3334. Rich is affiliated with the Aledade 201 National MSSP (ACO ID: A5522), participating under the MSSP model.

Rich's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 262 traditional Medicare patients, billed 66,874 HCPCS/CPT codes, and received $1,727,028 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 665 prescription claims across 123 beneficiaries totaling $3,099,872 in drug costs, led by Ibrance (Palbociclib). DME data shows 22 claims. Open Payments data shows 128 records totaling $9,704. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $617,550 to $1,727,028. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $542,016 to $3,099,872. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $456 to $4,364.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	254	61,224	$617,550
2016	307	61,417	$1,151,589
2017	338	73,261	$1,301,593
2018	305	82,736	$1,546,730
2019	333	94,111	$1,636,384
2020	287	82,612	$1,559,539
2021	276	82,504	$1,613,855
2022	276	101,690	$1,876,953
2023	279	89,550	$1,688,557
2024	262	66,874	$1,727,028

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	107	568	$542,016
2016	127	662	$749,164
2017	145	707	$804,490
2018	133	701	$1,309,133
2019	115	599	$1,416,629
2020	129	607	$1,165,993
2021	121	545	$1,571,992
2022	136	655	$1,933,820
2023	133	635	$1,945,763
2024	123	665	$3,099,872

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	24	$11,695
2017	N/R	44	$6,243
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	11	$2,087
2021	N/R	78	$7,996
2022	N/R	38	$3,132
2023	N/R	81	$6,900
2024	N/R	22	$4,357

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	160	603	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	118	219	$65
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	169	473	$12
80053	Blood test, comprehensive group of blood chemicals	181	794	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	190	902	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	39	1,085	$621,228
Revlimid	Lenalidomide	25	700	$374,532
Venclexta	Venetoclax	22	660	$314,955
Lenalidomide	Lenalidomide	20	560	$302,360
Tagrisso	Osimertinib Mesylate	12	360	$197,480

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	N/R	22	$4,357

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	126	$9,704	Tempus AI, Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	2	$7,071	Cornerstone Specialty Network LLC

Explore More Providers

FAQ

What Medicare data is available for Nathan Terry Rich, M.D.?

Tedicare shows public-source Medicare data for Nathan Terry Rich, M.D. (NPI 1396778148), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Nathan Terry Rich, M.D. have ACO affiliation data?

Nathan Terry Rich, M.D. is shown with ACO affiliation data for Aledade 201 National MSSP (MSSP, ACO ID A5522).

What billing organization is linked to Nathan Terry Rich, M.D.?

Nathan Terry Rich, M.D. is linked to UTAH CANCER SPECIALISTS PC (billing NPI 1619925369) in the available physician profile data.

Does Nathan Terry Rich, M.D. have Open Payments data?

Nathan Terry Rich, M.D. has 128 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.